Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05559112
Other study ID # IRB-2022-750
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 5, 2022
Est. completion date April 2024

Study information

Verified date February 2024
Source Purdue University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We propose to assess the effects of including vitamin D-enriched mushrooms as part of participants' usual eating pattern primarily on 25(OH) vitamin D2 status and secondarily on immune function and inflammatory status.


Description:

We hypothesize that consuming vitamin D-enriched mushrooms daily for 12 weeks will prevent decreases in serum 25-hydroxy-vitamin D2 concentrations. Secondarily, we hypothesize consuming vitamin D-enriched mushrooms daily for 12 weeks will improve clinical indicators of inflammatory status and alter/enhance immune status and immune cell function. This short-term randomized, controlled trial will provide important data to inform the plausibility, focus, and design of longer-term intervention trials, consistent with The Mushroom Council's research agenda regarding health-promoting effects of vitamin D-enriched mushrooms.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 69 Years
Eligibility Inclusion Criteria: - BMI: 25.0-34.9 kg/m^2 - Total cholesterol <240 mg/dL - low density lipoprotein cholesterol < 160 mg/dL - triglycerides <300 mg/dL - fasting glucose < 110 mg/dL - systolic/diastolic blood pressure < 140/90 mmHg - body weight stable for 3 months prior (+- 3 kg) - stable physical activity regiment 3 months prior - medication use stable for 6 months prior - non-smoking - non-diabetic - not acutely ill - females not pregnant or lactating - willing to refrain from taking vitamin D supplements or any supplements containing vitamin D - No history of bariatric surgery - Not extremely or severely depressed (Beck's Depression Inventory Score <= 30) - Agree not to donate blood for at least one month prior to, during, and for one month after the study - Agree not to travel to sunny locations during the study period - Agree to forgo any tanning bed or other tanning procedures during the study - Willing and able to consume mushrooms and travel to testing facilities Exclusion Criteria: - Age <30 or >70 - BMI <25 or >35kg/m2 - Total cholesterol >240 mg/dL, low-density lipoprotein cholesterol >160 mg/dL, triglycerides >300mg/dL, fasting glucose >110 mg/dL - Systolic/diastolic blood pressure >140/90 mm Hg - Body weight changes in previous 3 months (±3 kg) - Changes in physical activity regimen in the previous 3 months - Medication changes in the previous 6 months - Extremely or severely depressed (Beck's Depression Inventory Score >30) - Unwilling to refrain from taking vitamin D supplements or any supplements containing vitamin D - Regiment of megadosing vitamin D - Unwilling to not to travel to sunny locations during the study period - Unwilling to forgo any tanning bed or other tanning procedures during the study - History of bariatric surgery - Consuming a restricted diet (such as keto, gluten free, high protein, low carb, etc.) - Smoking - Diabetic - Acute illness - Females pregnant or lactating - Unwilling to not to donate blood for at least one month prior to, during, and for one month after the study - Allergic to mushrooms or bread

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Vitamin D-enriched mushrooms
Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
Study Powder
Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.

Locations

Country Name City State
United States Purdue University, Department of Nutrition Science West Lafayette Indiana

Sponsors (1)

Lead Sponsor Collaborator
Purdue University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in serum 25-hydroxy-vitamin D2 concentration 25(OH) Vitamin D2/D3 by LC/MS 12 weeks
Secondary Change in immunity/inflammation markers Immunoglobulin G, Immunoglobulin A, Immunoglobulin M (mg/dL) 12 weeks
Secondary Change in immunity/inflammation markers High Sensitivity C Reactive Protein (hs-CRP) 12 weeks
Secondary Change in immunity/inflammation markers Cytokine 13 Panel (pg/mL) 12 weeks
Secondary Change in bone remodeling Osteocalcin 12 weeks
Secondary Change in serum calcium concentrations Parathyroid hormone (PTH) 12 weeks
Secondary Change in perceived depression from baseline to mid to post-intervention Beck's Depression Inventory questionnaire 12 weeks
Secondary Change in perceived anxiety from baseline to mid to post-intervention Patient Health Questionnaire-9 12 weeks
Secondary Change in cognitive function from baseline to mid to post-intervention Repeatable Battery for the Assessment of Neuropsychological Status 12 weeks
Secondary Change in perceived daily mood from baseline to mid to post-intervention Profile of Mood States 12 weeks
Secondary Change in perceived quality of life from baseline to mid to post-intervention Medical Outcomes Study 36-Item Short Form Health Survey Version 2 12 weeks
Secondary Risk factors for cardiovascular disease Complete metabolic panel 12 weeks
Secondary Risk factors for cardiovascular disease Blood pressure 12 weeks
Secondary Risk factors for cardiovascular disease Lipoprotein Particle Plus (LPP+) Panel 12 weeks
Secondary Risk factors for cardiovascular disease Complete blood count (CBC) 12 weeks
Secondary Risk factors for type 2 diabetes Complete metabolic panel 12 weeks
Secondary Body weight Measures of weight (kg) 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Recruiting NCT05459298 - ViDES Trial (Vitamin D Extra Supplementation) N/A
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04476511 - The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules Phase 3
Completed NCT03920150 - Vitamin D 24'000 IU for Oral Intermittent Supplementation Phase 3
Completed NCT03264625 - The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis Phase 2
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT05506696 - Vitamin D Supplementation Study N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Completed NCT03234218 - Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT02906319 - Vitamin D and HbA1c Levels in Diabetic Patients With CKD N/A
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT02118129 - Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'. N/A
Not yet recruiting NCT01419821 - Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5 N/A
Completed NCT02187146 - The Effects of Serum Vitamin D and IVF Outcome N/A
Completed NCT02275650 - The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter N/A
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3
Completed NCT01688102 - The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile N/A